Monday 18 May 2020

myNEO and eTheRNA collaborate to investigate the immunogenicity of a long non-coding RNA

myNEO and eTheRNA announce a research programme to investigate a promising long non-coding RNA as a source of immunogenic targets for therapeutic use.

For therapeutic vaccination in cancer the selection of the correct antigen candidates is crucial. In this respect, long non-coding RNA (lncRNA) has been found to potentially be a promising source of neo-antigens.

In this research programme, myNEO will determine whether small peptides derived from lncRNA are presented on the surface of a cancer cell line in vitro. Subsequently  the  immunogenicity of the peptides will be assessed via in-silico prediction mechanisms developed by myNEO. The ultimate goal is to bring the most promising immunogenic targets to the patient using eTheRNA’s mRNA-based vaccine technology platform.

About eTheRNA

eTheRNA immunotherapies is a clinical-stage Belgian biotech company applying mRNA-based immunotherapies to the treatment of cancer and infectious disease. The proprietary TriMix mRNA technology stimulates and educates specifically dendritic cells to create a potent and durable immune response. eTheRNA’s goal is to commercialise these immunotherapies to deliver long lasting clinical remission to cancer patients and protective immunity against infections.